COVID-19 in people with HIV in the Netherlands.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 09 2023
Historique:
medline: 4 8 2023
pubmed: 18 5 2023
entrez: 18 5 2023
Statut: ppublish

Résumé

We investigated occurrence of and risk factors for severe COVID-19 outcomes in people with HIV (PWH) in the Netherlands. An ongoing prospective nationwide HIV cohort study. COVID-19 diagnoses and outcomes with other relevant medical information were prospectively collected from electronic medical records in all HIV treatment centers in the Netherlands, from the start of the COVID-19 epidemic until December 31, 2021. Risk factors for COVID-19 related hospitalization and death were investigated using multivariable logistic regression, including demographics, HIV-related factors, and comorbidities. The cohort comprises 21 289 adult PWH, median age 51.2 years, 82% male, 70% were of Western origin, 12.0% were of sub-Saharan African and 12.6% Latin American/Caribbean origin, 96.8% had HIV-RNA less than 200 copies/ml, median CD4 + cell count 690 (IQR 510-908) cells/μl. Primary SARS-CoV-2 infections were registered in 2301 individuals, of whom 157 (6.8%) required hospitalization and 27 (1.2%) ICU admission. Mortality rates were 13 and 0.4% among hospitalized and nonhospitalized individuals, respectively. Independent risk factors for severe outcomes (COVID-19-related hospitalization and death) were higher age, having multiple comorbidities, a CD4 + cell count less than 200 cells/μl, uncontrolled HIV replication, and prior AIDS diagnosis. Migrants from sub-Saharan Africa, Latin America, and the Caribbean were at an increased risk of severe outcomes independently of other risk factors. In our national cohort of PWH, risk of severe COVID-19 outcomes was increased in individuals with uncontrolled HIV replication, low CD4 + cell count, and prior AIDS diagnosis, independently of general risk factors such as higher age, comorbidity burden and migrants originating from non-Western countries.

Identifiants

pubmed: 37199566
doi: 10.1097/QAD.0000000000003597
pii: 00002030-990000000-00260
pmc: PMC10399951
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1671-1681

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Références

Lancet HIV. 2021 Nov;8(11):e701-e710
pubmed: 34655549
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Am J Epidemiol. 2021 Aug 1;190(8):1510-1518
pubmed: 33710317
AIDS. 2022 Dec 1;36(15):2171-2179
pubmed: 36382436
Open Forum Infect Dis. 2022 May 17;9(6):ofac257
pubmed: 35783684
J Migr Health. 2022;5:100086
pubmed: 35194589
Ann Intern Med. 2021 Apr;174(4):581-582
pubmed: 33872541
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
J Travel Med. 2022 Sep 17;29(6):
pubmed: 35417000
J Clin Med. 2022 Mar 31;11(7):
pubmed: 35407557
Clin Infect Dis. 2021 Oct 5;73(7):e1964-e1972
pubmed: 32905581
Scand J Public Health. 2021 Feb;49(1):48-56
pubmed: 33406993
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466
SSM Popul Health. 2021 Apr 16;14:100797
pubmed: 33997246
BMC Public Health. 2021 Sep 22;21(1):1721
pubmed: 34551752
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
Lancet Reg Health Eur. 2022 Feb;13:100284
pubmed: 34927120
AIDS. 2020 Nov 1;34(13):F3-F8
pubmed: 32796217
JAMA Netw Open. 2021 Dec 1;4(12):e2140529
pubmed: 34967887
J Acquir Immune Defic Syndr. 2021 Nov 1;88(3):e22
pubmed: 34334740
J Acquir Immune Defic Syndr. 2022 Aug 1;90(4):369-376
pubmed: 35364600
J Migr Health. 2021;3:100041
pubmed: 33903857
BMJ Open. 2018 Sep 24;8(9):e022516
pubmed: 30249631
PLoS One. 2021 May 3;16(5):e0250602
pubmed: 33939733
Lancet HIV. 2021 Nov;8(11):e690-e700
pubmed: 34655550
Vaccine. 2021 Apr 8;39(15):2024-2034
pubmed: 33722411
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
AIDS. 2022 Oct 1;36(12):1689-1696
pubmed: 35848570
J Epidemiol Community Health. 2020 Nov 28;:
pubmed: 33249407
Curr Opin HIV AIDS. 2021 Jan;16(1):54-62
pubmed: 33165007
AIDS. 2022 Feb 1;36(2):161-168
pubmed: 34934017
PLoS One. 2021 Dec 1;16(12):e0260251
pubmed: 34851963
AIDS. 2021 Sep 1;35(11):1875-1878
pubmed: 34397487
Dig Dis Sci. 2023 Jun;68(6):2731-2737
pubmed: 36737575
AIDS Behav. 2022 Jul;26(7):2256-2265
pubmed: 35024992
Lancet HIV. 2021 May;8(5):e294-e305
pubmed: 33915101
Clin Infect Dis. 2021 Jun 15;72(12):e1021-e1029
pubmed: 33252620
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Eur J Health Econ. 2020 Sep;21(7):977-982
pubmed: 32591957
HIV Med. 2021 May;22(5):372-378
pubmed: 33368966
BMC Public Health. 2022 Apr 14;22(1):750
pubmed: 35422031
Infection. 2021 Feb;49(1):15-28
pubmed: 32860214
J Antimicrob Chemother. 2022 Jul 28;77(8):2265-2273
pubmed: 35678461

Auteurs

Ferdinand W N M Wit (FWNM)

Stichting HIV Monitoring.
Amsterdam University Medical Centers, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam.

Peter Reiss (P)

Stichting HIV Monitoring.
Amsterdam University Medical Centers, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam.

Bart Rijnders (B)

Erasmus University Medical Center, Departments of Internal Medicine & Medical Microbiology, Rotterdam.

Casper Rokx (C)

Erasmus University Medical Center, Departments of Internal Medicine & Medical Microbiology, Rotterdam.

Anna Roukens (A)

Leiden University Medical Center, Department of Internal Medicine, Leiden.

Kees Brinkman (K)

Onze Lieve Vrouwe Gasthuis, Department of Internal Medicine, Amsterdam, Netherlands.

Marc van der Valk (M)

Stichting HIV Monitoring.
Amsterdam University Medical Centers, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection & Immunity Institute, Amsterdam.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH